Long-term follow-up of nephron sparing surgery for renal cell carcinoma
10.3760/cma.j.issn.1000-6702.2010.03.002
- VernacularTitle:肾细胞癌保留肾单位手术的长期随访
- Author:
Xishuang SONG
;
Feng CHEN
;
Dongjun WU
;
Zhongzhou HE
;
Quanlin LI
;
Xiangyu CHE
;
Jianbo WANG
;
Jibin YIN
;
Xiancheng LI
;
Zhiwei ZHANG
- Publication Type:Journal Article
- Keywords:
Carcinoma,renal cell;
Nephron sparing surgery;
Prognosis
- From:
Chinese Journal of Urology
2010;31(3):153-156
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the long-term therapeutic results and the safety of nephronsparing surgery(NSS) for the treatment of renal cell carcinoma. Methods Clinical data of 243 NSSfor renal cell carcinoma were retrospectively analysed. Of them, 159 were males and 84 were femaleswith average age of 58 years (range from 24 ?77 years). The average tumor size was 3. 4 cm (rangefrom 1.1 to 6. 7 cm). Three cases were solitary renal cell carcinoma, 11 were bilateral renal cell carcinoma; 237 cases were in stage T_(1a). and 6 cases were in stage T_(1b). No lymph node and distant metastasis, no renal vein cancer tumor embolus and inferior vena cava tumor embolus was found. Postoperative follow-up was carried out by ultrasound, CT and renal function. Cancer specific survival was estimated using Kaplan-Meier method and log-rank test. Results After a mean 31 months (1-147months) follow-up, long-term follow-up data were obtained in 232 cases because the other 11 did notlive in Dalian, 52 were treated with interferon. Four of the 232 patients treated with NSS had died:1died from lung cancer 16 months after lung cancer treatment, the other 3 died from cardiovascular diseases. The total survival rate and cancer specific survival rate were 98. 3% and 100. 0%, respectively.Local tumor recurrences were detected in 5 patients and tumor metastasis was detected in 1 patient.The recurrence rate was 2. 2%, and the metastasis rate was 0. 4%. The complications included temporary renal failure and urine leakage. The complication rate was 5. 6%. Conclusions NSS for renalcell carcinoma is a safe and feasible treatment option. It has the advantages of low local recurrence,good long-term survival rate and low complication rate. NSS can maximally reserve functional nephron, reduce the risk of chronic renal failure, preserve patient's quality of life and increase patient'ssatisfaction.
